Stephen Brown, PA
Physician Assistant · Ontario, OHNPI 1073274163
Payments from drug & device makers
Across 391 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$991
- Bayer$797
- Novartis$700
- Corcept Therapeutics$434
- Amgen$327
- plus $3K from 25 others
What the payments were for
- Food & beverage$7,16599%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 63 | $1,091 |
| AstraZeneca | 43 | $991 |
| Bayer | 45 | $797 |
| Novartis | 36 | $700 |
| Corcept Therapeutics | 28 | $434 |
| Amgen | 21 | $327 |
| GSK | 16 | $313 |
| Novo Nordisk | 18 | $300 |
| Pfizer | 20 | $292 |
| Exact Sciences | 11 | $232 |
| Lilly USA, LLC | 14 | $231 |
| Phathom Pharmaceuticals, Inc. | 14 | $226 |
| Esperion Therapeutics, Inc. | 10 | $177 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $166 |
| Johnson & Johnson | 6 | $128 |
| Teleflex LLC | 1 | $116 |
| Otsuka America Pharmaceutical, Inc. | 4 | $93 |
| Xeris Pharmaceuticals, Inc. | 4 | $79 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $67 |
| Boston Scientific | 2 | $66 |
| OPKO Pharmaceuticals, LLC | 3 | $51 |
| Aimmune Therapeutics, Inc. | 3 | $50 |
| Optinose US, Inc. | 2 | $47 |
| Idorsia Pharmaceuticals US Inc | 3 | $45 |
| Dexcom, Inc. | 2 | $45 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $30 |
| Boehringer Ingelheim | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,216 in reported general payments places this provider in the 95th percentile of 4,098 physician assistant providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 63 | $65,379 |
| JardianceEmpagliflozin | 42 | $56,886 |
| FarxigaDapagliflozin Propanediol | 48 | $33,064 |
| OzempicSemaglutide | 28 | $31,937 |
| XareltoRivaroxaban | 14 | $14,921 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $11,890 |
| EntrestoSacubitril/Valsartan | 13 | $10,075 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,758 |
| Praluent PenAlirocumab | 12 | $5,672 |
| SynthroidLevothyroxine Sodium | 77 | $3,852 |
| Atorvastatin Calcium | 401 | $3,213 |
| Levothyroxine Sodium | 229 | $1,951 |
| Metoprolol Succinate | 143 | $1,878 |
| Amlodipine Besylate | 326 | $1,819 |
| Omeprazole | 175 | $1,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $292 | $65,37963 claims |
| Boehringer IngelheimJardiance | $20 | $56,88642 claims |
| AstraZenecaFarxiga | $991 | $33,06448 claims |
| Novo NordiskOzempic | $300 | $31,93728 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $313 | $17,64931 claims |
| Johnson & JohnsonXarelto | $128 | $14,92114 claims |
| NovartisEntresto | $700 | $10,07513 claims |
| AbbVieSynthroid | $1,091 | $3,85277 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,098 physician assistant providers in Ohio.
Other physician assistant in Ontario
- Steven WurzelbacherCincinnati$309K
- Emily AnkromDayton$192K
- Amanda MaggartWorthington$164K
- Megan SevillaMayfield Heights$132K
- Erin StrculaBelpre$106K
- Natalie WalkupSylvania$105K
- Sarah LaubNew Albany$100K
- Jessica RhominskiCanal Winchester$78K
- Alan OdonnellCincinnati$71K
- Brook GramBeloit$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.